Dermal micro-organs, methods and apparatuses for producing and using the same
First Claim
1. A method of delivering at least one recombinant gene product selected from growth hormone, interferon β
- , insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10), and G-CSF to a subject comprising implanting into or underneath the skin at least one genetically modified dermal micro-organ that expresses and secretes said at least one recombinant gene product or at least a portion of said at least one recombinant gene product,a. wherein said at least one recombinant gene product comprises growth hormone, interferon β
, insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10) or G-CSF;
b. wherein said genetically modified dermal micro-organ is autologous with said subject;
c. wherein said dermal micro-organ is an explant of living tissue consisting essentially of a plurality of dermal components and lacking a complete epidermal layer that substantially maintains the micro-architecture and three-dimensional structure of the dermal tissue from which it is obtained, and having dimensions allowing passive diffusion of nutrients and gases to cells of said dermal micro-organ and diffusion of cellular waste out of said cells;
d. wherein at least some of the cells of said genetically modified dermal micro-organ express and secrete at least a portion of said at least one recombinant gene product; and
e. wherein said implanting of said at least one genetically modified dermal micro-organ delivers growth hormone, interferon β
, insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10) or G-CSF, or at least a portion of thereof, to said subject.
0 Assignments
0 Petitions
Accused Products
Abstract
Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.
63 Citations
14 Claims
-
1. A method of delivering at least one recombinant gene product selected from growth hormone, interferon β
- , insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10), and G-CSF to a subject comprising implanting into or underneath the skin at least one genetically modified dermal micro-organ that expresses and secretes said at least one recombinant gene product or at least a portion of said at least one recombinant gene product,
a. wherein said at least one recombinant gene product comprises growth hormone, interferon β
, insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10) or G-CSF;b. wherein said genetically modified dermal micro-organ is autologous with said subject; c. wherein said dermal micro-organ is an explant of living tissue consisting essentially of a plurality of dermal components and lacking a complete epidermal layer that substantially maintains the micro-architecture and three-dimensional structure of the dermal tissue from which it is obtained, and having dimensions allowing passive diffusion of nutrients and gases to cells of said dermal micro-organ and diffusion of cellular waste out of said cells; d. wherein at least some of the cells of said genetically modified dermal micro-organ express and secrete at least a portion of said at least one recombinant gene product; and e. wherein said implanting of said at least one genetically modified dermal micro-organ delivers growth hormone, interferon β
, insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10) or G-CSF, or at least a portion of thereof, to said subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- , insulin, PDGF-BB, interleukin 1 receptor agonist (IL-1Ra), peptide YY3-36, interleukin 10 (IL-10), and G-CSF to a subject comprising implanting into or underneath the skin at least one genetically modified dermal micro-organ that expresses and secretes said at least one recombinant gene product or at least a portion of said at least one recombinant gene product,
Specification